Friday, September 4, 2026
← Back to archivePolicy
Policy•STAT News•Sep 4, 2026
Opinion: Make infectious disease data boring again
background ▾
- •Politicization of infectious disease case definitions and death classifications undermines the standardized data collection processes essential for national disease surveillance and outbreak response
- •The Health Secretary has promoted vaccine misinformation (falsely claiming MMR causes more deaths than measles, overstating vitamin A benefits) and questioned established measles deaths during an active outbreak, eroding public trust in CDC guidance
- •State-federal collaboration on infectious disease response is at risk if case definitions become subject to political interpretation rather than epidemiologic consensus, potentially degrading the nation's outbreak detection and response capabilities
measles, mumps, and rubella vaccinevitamin A
→ Read original articlePolicy•STAT News•Sep 4, 2026
Opinion: The FDA removed the red tape around one of the best drugs for children with schizophrenia. But the fear remains
background ▾
- •FDA eliminated the 30+ year mandatory REMS program for clozapine, removing registry enrollment and frequent blood draw requirements that created administrative barriers to prescribing
- •Clozapine remains dramatically underutilized (4% vs. potential 33% of schizophrenia patients) due to clinician fear of side effects rather than regulatory burden, particularly in treatment-resistant and childhood-onset schizophrenia
- •Watch for: whether the REMS removal translates to increased clozapine prescribing rates in practice, and whether medical education and physician confidence-building efforts emerge as the next critical lever for patient access to this uniquely effective therapy
clozapine
→ Read original articlePolicy•STAT News•Sep 3, 2026
‘Tactical athletes’ get new guidance for cardiovascular fitness
background ▾
- •First formal clinical guidance specifically developed for tactical athletes, filling a gap that existed between competitive sports cardiology guidance and general population health standards
- •Cardiovascular disease is the leading duty-related cause of death in tactical athletes, with elevated risk during recruit training and emergency response situations
Policy•STAT News•Sep 3, 2026
HHS flip-flops on disability lawsuit
background ▾
- •The DOJ joining the states' lawsuit signals the federal government's intent to cease enforcement of the community integration mandate under Section 504, marking a dramatic policy reversal on disability rights protections
- •Success in this litigation could potentially overturn decades of legal precedent requiring community-based care for disabled individuals receiving federally-funded services
- •Monitor developments in disability law and potential impacts on institutional vs. community-based healthcare delivery models for vulnerable populations
Policy•Fierce Biotech•Sep 2, 2026
Novartis telegraphs 130 job cuts amid biologics rethink in Switzerland
background ▾
- •Novartis is eliminating 130 jobs at Kleinbasel and consolidating biologics production into a centralized technical development center on its Basel campus, signaling a strategic pivot toward higher-complexity manufacturing
- •This restructuring is part of a larger European manufacturing footprint reduction (900+ jobs cut across Switzerland and Germany since 2025) as the company transitions to advanced therapies and sterile dosage forms
Novartis
→ Read original articleMarket Access
Market Access•Fierce Biotech•Sep 3, 2026
Pfizer offloads scrapped Seagen ADC to Medicus Pharma in up to $1B+ deal
background ▾
- •Pfizer has systematically divested Seagen assets post-acquisition, signaling significant integration challenges and strategic misalignment with the $43B deal thesis
- •CD228V remains early-stage (discontinued phase 1) with no approved competitors in the target space, representing meaningful clinical and commercial risk that Medicus has accepted
- •Pfizer's royalty and >$1B milestone participation preserves upside exposure while transferring operational and financial burden to a smaller partner
PfizerSeagenMedicus PharmaPF-08046031CD228V
→ Read original articleMarket Access•Fierce Biotech•Sep 3, 2026
GSK pens $1.3B Hutchmed deal for early-stage KRAS-EGFR cancer asset
background ▾
- •GSK secures exclusive worldwide rights (ex-Asia) to a novel dual KRAS-EGFR mechanism potentially addressing limitations of current monotherapy KRAS inhibitors
- •Early-stage asset entering Phase 1 in 2024 with significant commercial milestones attached ($1.3B total), indicating GSK's confidence in mechanism despite recent KRAS class setbacks
- •Monitor Phase 1 safety/tolerability data and BMS Krazati's confirmatory trial outcomes, which will inform competitive positioning of dual-targeting approaches in KRAS-mutant solid tumors
GSKHutchmedBristol Myers SquibbHMPL-A830KrazatiTagrisso
→ Read original articleMarket Access•Endpoints News•Sep 3, 2026
Merck's top dealmaker signals more M&A as Keytruda's patent cliff nears
background ▾
- •Merck is pursuing acquisitions strategically to mitigate revenue risk from Keytruda's looming patent cliff
- •CEO Davis explicitly framing M&A as urgent, indicating internal pressure to rebuild the pipeline before major revenue headwinds
- •Watch for announcement of specific Merck acquisitions and their therapeutic focus areas over the next 12-24 months
MerckKeytruda
→ Read original articleMarket Access•Endpoints News•Sep 3, 2026
Novartis' drug delivery deal with Alteogen; More worker cuts at Cellares
background ▾
- •Novartis is licensing Alteogen's hyaluronidase technology to expand its drug delivery capabilities, signaling continued investment in enabling technologies despite industry cost-cutting
- •The deal's scope, financial terms, and specific drug candidates to benefit from the technology remain undisclosed, limiting assessment of commercial impact
NovartisAlteogenCellareshyaluronidase
→ Read original articleMarket Access•Endpoints News•Sep 3, 2026
Pfizer shares ADC rights with Medicus; RevMed updates lung cancer data
background ▾
- •Pfizer is externalizing development risk on a CD228 ADC through a co-development partnership with Medicus Pharma
PfizerMedicus PharmaRevMedCD228-targeted antibody-drug conjugate
→ Read original articleClinical Trials
Clinical Trials•Fierce Biotech•Sep 3, 2026
Ultragenyx fails phase 3 Angelman test, plots ‘significant expense reductions’
background ▾
- •Apazunersen missed both primary (Bayley-4 cognitive raw score change) and secondary (Multidomain Responder Index) endpoints in the Aspire phase 3 trial, with no pathway forward yet defined for the program
- •The clinical failure portends challenges for Ultragenyx's companion Aurora trial and undermines investor confidence despite recent Genglycos approval, prompting workforce and operational restructuring
- •Monitor Ultragenyx's September 19 PDUFA decision for UX111 in Sanfilipo syndrome and any updates on apazunersen disposition within weeks; competitive threat from Ionis' obudanersen (phase 3 enrollment complete) in Angelman syndrome
UltragenyxIonisapazunersenGenglycos (pariglasgene brecaparvovec-opnr)UX111
→ Read original articleClinical Trials•Fierce Biotech•Sep 3, 2026
AbbVie’s bispecific T-cell engager shows promise in ph. 3 multiple myeloma trial
background ▾
- •Etentamig demonstrated substantial improvement in response rates (74% vs 45.7%) and progression-free survival (60% risk reduction) in heavily pretreated relapsed/refractory multiple myeloma patients, with efficacy consistent across all subgroups
- •The monthly dosing regimen achieved a differentiated safety profile with predominantly grade 1 CRS, no grade 3+ ICANS, and paradoxically lower grade 5 infection rates than standard therapies (1.5% vs 3.1%), supporting potential community/outpatient use
- •Overall survival boundary not yet crossed at interim analysis; full results presentation at IMS Annual Meeting (September 2024) and upcoming regulatory discussions will be critical to assess path to approval and commercial potential in a large incurable disease area
AbbVieetentamigABBV-383
→ Read original articleClinical Trials•Fierce Biotech•Sep 3, 2026
Psilocybin proves promising in neuropathic pain mouse study
background ▾
- •Psilocybin prevented CIPN-related pain hypersensitivity in mice through 5-HT2A receptor agonism preserving mitochondrial transport in peripheral neurons, suggesting a novel mechanistic approach to a major chemotherapy side effect affecting nearly 30% of patients long-term.
- •This represents early-stage preclinical work in a mouse model with unproven translation to human efficacy and safety; substantial clinical development would be required before any therapeutic application.
- •Watch for: potential clinical trial initiation at MD Anderson and regulatory pathways under FDA's April 2026 psychedelics prioritization mandate; competitive positioning as major pharma (AbbVie, Otsuka, Eli Lilly) rapidly consolidate psychedelics pipelines.
University of Texas MD Anderson Cancer CenterEli LillyAbbViepsilocybinCymbaltabretisilocin
→ Read original articleClinical Trials•Fierce Biotech•Sep 3, 2026
Why Roche is 'really excited' about a UCN2 analog for obesity after seeing preclinical data
background ▾
- •Roche paid $190M upfront for HM17321, a novel non-incretin obesity asset designed to achieve weight loss while preserving lean muscle mass and improving muscle function—a mechanistic advantage over current GLP-1/GIP agents.
- •The acquisition strengthens Roche's three-pillar obesity strategy (incretins, amylins, FGF21 analogs) by adding a CRF2 agonist to address lean mass preservation and metabolic dysfunction—critical comorbidity concerns in elderly and fall-risk populations.
- •Phase 1 data from Hanmi is the near-term catalyst; Roche aims to initiate phase 2 rapidly if human efficacy/safety profile supports the preclinical promise, but executive commentary acknowledges translation risk and the need for clinical proof before full confidence.
RocheGenentechHanmi PharmHM17321enicepatideCT-996
→ Read original articleClinical Trials•Endpoints News•Sep 3, 2026
Summit, Akeso say ivonescimab clears OS bar in Phase 3 lung cancer trial
background ▾
- •Ivonescimab achieved statistical significance on OS in Phase 3 lung cancer, overcoming prior interim disappointment and de-risking the program
- •China-only trial design limits immediate global commercial applicability and raises questions about the necessity or timeline for broader geographic expansion
- •Regulatory path in China and potential international development strategy remain critical unknowns for commercialization scope
AkesoSummit Therapeuticsivonescimab
→ Read original article